Concepedia

Author

Tereza Lanitis

EVRAZ (United Kingdom)ORCID

Also Known As

T Lanitis, T. Lanitis, Tereza Lanitis

50

Publications

866

Citations

14

H-Index

40

Concepts

All Affiliations

EVRAZ (United Kingdom)Pfizer (United States)Ithaka HarborsBristol-Myers Squibb (United States)Regeneron (United States)
TL

About

Tereza Lanitis is an author at EVRAZ (United Kingdom) specializing in medicine, public health, and health policy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

93

2

Public Health

4

4

68

3

Health Policy

3

3

53

4

Emergency Medicine

1

1

16

5

Epidemiology

1

1

15

Tereza Lanitis

×

15

Publications

492

Citations

13

H-Index

YearCitations

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

Paul Dorian, Thitima Kongnakorn, Hemant Phatak,

European Heart Journal

2014

94

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Gregory Y.H. Lip, Thitima Kongnakorn, Hemant Phatak,

Clinical Therapeutics

2014

83

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

Tereza Lanitis, François-Emery Cotté, Anne-Françoise Gaudin,

Journal of Medical Economics

2014

70

Social Cost of Blindness Due to AMD and Diabetic Retinopathy in the United States in 2020

Andrew A. Moshfeghi, Tereza Lanitis, Georg Kropat,

Ophthalmic surgery, lasers & imaging retina

2020

33

Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation

Tereza Lanitis, Thitima Kongnakorn, Lena Jacobson,

Thrombosis Research

2014

30

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-effectiveness Analysis

L Hernandez, Tereza Lanitis, Clifford Cele,

Journal of Managed Care & Specialty Pharmacy

2018

26

Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin

Thitima Kongnakorn, Tereza Lanitis, Lieven Annemans,

Clinical Drug Investigation

2014

25

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis

Luis Hernández, Tereza Lanitis, Clifford Cele,

Journal of Managed Care & Specialty Pharmacy

2018

25

Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA

Mustafa Oğuz, Tereza Lanitis, Xiaoyan Li,

Applied Health Economics and Health Policy

2019

23

Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium

Thitima Kongnakorn, Tereza Lanitis, Lievens Annemans,

Clinical Drug Investigation

2014

16

Page 1